At Reig Jofre, we have a clear purpose: universalizing science that matters.
We develop, manufacture, market, and distribute essential, science-based health solutions, from the most critical treatments to products focused on prevention and wellness. This purpose drives every decision, every innovation and every breakthrough we pursue: to bring pharmaceutical solutions to more people, at more stages of their lives, with the highest standards of efficacy and safety.
With over 95 years of experience, Reig Jofre is a leading European pharmaceutical company that combines science, technology, and industrial expertise to support a more
accessible, efficient, and humane healthcare system. We operate four development and production centers, eight commercial offices, and maintain a robust international distribution network spanning more than 70 countries.
Reig Jofre markets its own brands and provides specialized manufacturing and strategic services for third parties. The company is listed on the Spanish Stock Exchange under the
ticker: RJF.
MedMe is building the operating system for the pharmacies of the future, powering their transformation from dispensaries to community healthcare hubs.
Our mission is to build an all-in-one cloud-based platform that empowers pharmacists to schedule, document, and manage clinical services at scale. Our clients include the 2 largest pharmacy chains in Canada, servicing 3000+ pharmacies, and powering over ~14M patient services, including playing a critical role across the country throughout the pandemic.
We have raised over $3.7M USD to date including from M12 (Microsoft’s Venture Fund), MaRS IAF, and Y-Combinator.
We're building on our rapid growth and role throughout the pandemic to take our modular platform to the next level; providing community pharmacies of all sizes and geographies the transformative technology to service high-quality care experiences and accessible healthcare offerings to their patients.
We're growing across Engineering, Customer Success, Product and more: jobs.lever.co/bloom?team=MedMe
Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey.
The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented at ASH 2025, with additional data expected at EHA 2026.
Vafidemstat, its lead CNS candidate, is in clinical development across neuropsychiatric indications, including aggression in borderline personality disorder (Phase III in preparation), negative symptoms of schizophrenia (ongoing Phase IIb) and aggression in autism spectrum disorder (ASD), including genetically defined populations such as Phelan-McDermid syndrome (Phase II in preparation).
Beyond LSD1, Oryzon is expanding its pipeline to new targets such as HDAC6, with ORY-4001 nominated for potential development in neurological diseases including ALS and CMT.
Oryzon also leverages a robust biomarker platform supporting precision medicine approaches. The Company is listed on the Spanish Stock Exchange (ORY) and has attracted specialized international investors from the United States and Europe.